Lambda Antibody Signal Peptide Cleavage Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibody production methods face challenges in the efficient secretion of antibody polypeptides into the endoplasmic reticulum, leading to cleavage heterogeneity and altered antibody properties due to non-specific signal peptide cleavage, which affects the N-terminus of heavy and light chains, impacting affinity and stability.
Innovation Solution
The use of specific signal peptides for λ light chain variable domains, which differ from native sequences, results in consistent expression of a single VL domain amino acid sequence, influencing the N-terminal sequence and properties of λ antibodies, allowing for the restoration of functional activity by adjusting the cleavage site to match the native or non-native signal peptide sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If non-specific signal peptide cleavage occurs during antibody production, then antibody secretion efficiency is improved, but cleavage heterogeneity increases leading to altered antibody properties
Solution Approach 1:
The patent applies parameter changes by modifying the signal peptide sequence to create an optimized version that maintains secretion efficiency while enabling specific cleavage. The optimized signal peptide contains specific amino acid changes that alter the cleavage site preference, ensuring consistent N-terminus sequences in the final antibody product while maintaining high secretion rates into the endoplasmic reticulum.
Solution Approach 2:
The optimized signal peptide acts as an intermediary element that mediates between the requirements for efficient secretion and precise cleavage. By designing a signal peptide with specific properties (optimized amino acid sequence), it serves as a bridge that enables both high productivity and manufacturing precision, controlling where and how the cleavage occurs to produce homogeneous N-termini.
2Quantity of substance
If signal peptide cleavage is enhanced to improve secretion, then antibody yield increases, but cleavage heterogeneity causes elongation or truncation of N-terminus
Solution Approach 1:
The patent changes the parameters of the signal peptide sequence to optimize both yield and precision. By introducing specific amino acid modifications in the signal peptide, the cleavage becomes more efficient (increasing yield) while simultaneously becoming more specific (preventing heterogeneity). The optimized sequence ensures that cleavage occurs at the intended site without elongation or truncation events.
Solution Approach 2:
The optimized signal peptide performs preliminary action by pre-determining the cleavage site through its engineered sequence. Before the actual cleavage event occurs, the signal peptide structure is already designed to guide proteases to the correct location, ensuring that when cleavage happens, it produces consistent N-terminus sequences and maximizes yield by preventing premature or incorrect cleavage events.
3Productivity
If modified signal peptides are used to increase antibody yields, then production efficiency improves, but folding, thermodynamic stability and aggregation propensities may be affected
Solution Approach 1:
The patent applies parameter changes to the signal peptide sequence in a controlled manner, modifying only the necessary regions (such as the cleavage site and adjacent residues) while leaving other critical regions intact. This selective modification approach increases production yield through improved cleavage efficiency while minimizing disruptions to the antibody's folding pathways and thermodynamic stability. The changes are tuned to achieve the desired balance between productivity and stability.
Solution Approach 2:
The optimized signal peptide applies local quality changes by modifying specific local regions of the signal peptide sequence rather than making global changes. The modifications are concentrated in the cleavage-dependent regions while preserving other portions of the signal peptide and the adjacent antibody sequences that are critical for proper folding and stability. This localized optimization ensures yield improvement without compromising overall protein quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures consistent and functional λ antibody production by controlling the N-terminal sequence of VL domains, enhancing the stability and activity of the antibodies by adjusting the cleavage site, thereby improving the efficiency of antibody production and reducing heterogeneity.
Implementation Method 1
The main production method for monoclonal antibodies is recombinant expression of nucleic acid encoding the antibody heavy and light chains in cultured host cells in vitro. In a typical production system, antibody heavy and light chains are co-translated and secreted from the host cell. One perceived bottleneck in the secretory pathway is translocation of the antibody polypeptides into the lumen of the endoplasmic reticulum (ER), via signal peptides.
Implementation Method 2
The signal peptide is a short (15-30 amino acid) sequence at the N terminus of the antibody heavy and light chains, which directs its translocation and is cleaved during the translocation process so is not a part of the secreted mature polypeptide chains.
Data Source
AI summary
Immunoglobulin lambda variable domain sequence adapted for expression with non-native N terminal signal peptide, comprising a deletion at IMGT position 1.